Acusphere has cancelled Cephalon’s $15 million Senior Secured Convertible Note. It has amended March and November 2008 License Agreements with Cephalon, for the oncology applications of Acusphere’s Hydrophobic
Pintek is an industry veteran with deep and broad experience in the life science industry. He joins Luminex from Roche, where he has held several positions of increasing
Financial Highlights Operating profit increased 17.9% to $13.2 million (2008: $11.2 million) EBITDA increased 13.9% to $15.6 million (2008: $13.7 million) and EBITDA margin increased to 29.7% (2008:
Osiris has reported six-month interim data from phase-II clinical trial, evaluating Prochymal for the treatment of chronic obstructive pulmonary disease (COPD). In the placebo-controlled study, 62 patients were
PharmaSwiss, Israeli licensee of BioSante Pharmaceuticals, has submitted a new drug application (NDA) for Elestrin in Israel. The Elestrin filing is based on BioSante’ FDA approved NDA for
GlaxoSmithKline (GSK) and Chroma Therapeutics have signed a collaboration agreement to develop macrophage-targeted compounds, using Chroma’ proprietary esterase-sensitive motif (ESM) technology. Chroma would undertake four discovery and development
Cerulean has signed a worldwide license agreement with Calando Pharma, a subsidiary of Arrowhead Research Corporation. Under the agreement, Cerulean has acquired worldwide rights to Calando’ proprietary cyclodextrin
PriCara, a division of Ortho-McNeil-Janssen Pharmaceuticals, has announced the launch of Nucynta (tapentadol) CII immediate release tablets. Nucynta works by binding with mu-opioid receptors and inhibiting norepinephrine re-uptake.
Cytopia has filed an Investigational New Drug Application (IND) with the FDA for orally active JAK2 inhibitor, CYT387. The company plans to start a phase I/II trial for
YM BioSciences’ licensee for nimotuzumab, Daiichi-Sankyo has initiated the enrollment of a phase II trial. It is to evaluate nimotuzumab, in combination with radiation therapy/cisplatin/vinorelbine, in first-line curative
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.